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Abstract
AIM: To investigate the weight loss and glycemic con-
trol status [blood glucose, hemoglobin A1c (HbA1c) 
and hypoglycaemic treatment].
METHODS: The primary risk factor for type 2 diabetes 
is obesity, and 90% of all patients with type 2 diabetes 
are overweight or obese. Although a remarkable effect 
of bariatric surgery is the profound and durable resolu-
tion of type 2 diabetes clinical manifestations, little is 
known about the difference among various weight loss 
surgical procedures on diabetes remission. Data from 
patients referred during a 3-year period (from January 
2009 to December 2011) to the University of Naples 
“Federico Ⅱ” diagnosed with obesity and diabetes were 
retrieved from a prospective database. The patients 
were split into two groups according to the surgical 
intervention performed [sleeve gastrectomy (SG) and 
mini-gastric bypass (MGB)]. Weight loss and glycemic 
control status (blood glucose, HbA1c and hypoglycae-
mic treatment) were evaluated.
RESULTS: A total of 53 subjects who underwent sleeve 
gastrectomy or mini-gastric bypass for obesity and 
diabetes were screened for the inclusion in this study. 
Of these, 4 subjects were excluded because of surgical 
complications, 7 subjects were omitted because young 
surgeons conducted the operations and 11 subjects 
were removed because of the lack of follow-up. Thirty-
one obese patients were recruited for this study. A 
total of 15 subjects underwent SG (48.4%), and 16 
underwent MGB (51.6%). After adjusting for various 
clinical and demographic characteristics in a multivari-
ate logistic regression analysis, high hemoglobin A1c 
was determined to be a negative predictor of diabetes 
remission at 12 mo (OR = 0.366, 95%CI: 0.152-0.884). 
Using the same regression model, MGB showed a clear 
trend toward higher diabetes remission rates relative to 
SG (OR = 3.780, 95%CI: 0.961-14.872).
CONCLUSION: Although our results are encouraging 
regarding the effectiveness of mini-gastric bypass on 
diabetes remission, further studies are needed to pro-
vide definitive conclusions in selecting the ideal proce-
dure for diabetes remission.
© 2013 Baishideng. All rights reserved.
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Core tip: Duodenum exclusion could suggest the poten-
tial superiority of mini-gastric bypass over sleeve gast-
rectomy to obtain diabetes remission. This mechanism 
could suggest the potential superiority of mini-gastric 
bypass over sleeve gastrectomy to obtain diabetes re-
mission. Thus, although the gold standard for diabetes 
remission is still the Roux-en-y gastric by pass, being 
similar mechanisms of diabetes remission involved and 
being easier to be performed, the mini-gastric by pass 
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INTRODUCTION
Severe obesity is one of  the major problems in Western 
Countries and is associated with several comorbidities 
and disabling diseases (e.g., cardiovascular disease, meta-
bolic syndrome, type 2 diabetes, fertility, certain tumor 
types and increased mortality)[1-6]. 
One of  the major comorbidities of  obesity is type 2 
diabetes mellitus (T2DM). In fact, the term “diabesity”[7] 
has been introduced to refer to obesity accompanied by 
T2DM. 
With the exception of  nutritional and some phar-
macological treatments, bariatric surgery is performed 
more and more frequently as the treatment of  choice in 
patients with severe obesity. 
The efficacy of  these surgical procedures in weight 
control has been widely described in several studies. 
Additionally, one of  the most relevant corollary effects 
reported following bariatric surgery is T2DM remission. 
A variety of  surgical procedures are available and, 
currently, it is difficult to identify the most effective op-
tion based on patient characteristics and comorbidities. 
Furthermore, little is known regarding the effect of  the 
various surgical procedures on glycemic control and on 
T2DM remission[8-11] .
The aim of  this study is to compare the clinical ef-
ficacy of  laparoscopic sleeve gastrectomy (SG) and lapa-
roscopic mini-gastric bypass (MGB) in terms of  T2DM 
remission.
MATERIALS AND METHODS
Data from patients referred during a 3-year period (from 
January 2009 to December 2011) to the University of  
Naples “Federico Ⅱ” diagnosed with obesity and diabe-
tes were retrieved from a prospective database.
Only patients who underwent uneventful laparoscop-
ic SG or MGB with a follow-up of  at least 1 year were 
included.
The patients were split into two groups according to 
the surgical intervention performed (SG and MGB).
Medical records were reviewed to collect the demo-
graphic and clinical characteristics of  the patients. Ac-
cording to standard procedures[12], the study population 
was stratified based on abdominal obesity [body mass 
index (BMI) > 30 kg/m2], triglycerides levels (equal to or 
> 150 mg/dL), HDL-cholesterol (< 40 mg/dL for men 
and 50 mg/dL for women with total cholesterol values 
> 200 mg/dL), blood pressure (systolic blood pressure 
equal to or > 130 and/or diastolic > 85 mmHg) and 
fasting glucose levels (equal to or > 110 mg/dL).
Diagnosis of  T2DM was made according to the 
American Diabetes Association guidelines. T2DM remis-
sion was defined as a fasting plasma glucose level below 
126 mg/dL in the absence of  hypoglycemic drugs. 
The indications for treating these patients were the 
same as those published in the Italian Society for Bariat-
ric Surgery guidelines[13]. Following the failure of  a non-
operative weight reduction program that included diet 
and other interventions (e.g., behavioral modification, 
psychotherapy, dietary counseling, or physical training), 
bariatric surgery plays a critical role in patient outcome 
when the BMI is > 40 kg/m2 or is > 35 kg/m2 com-
bined with serious co-existing conditions.
Only surgical procedures performed by an expert 
surgeon (more than 500 laparoscopic surgical proce-
dures) were included in the analysis.
Prevention of  surgical site infection and periopera-
tive antiplatelet drug administration were managed ac-
cording to validated criteria[14,15].
For the sleeve gastrectomy procedure, 75%-80% 
of  the greater curvature was excised, leaving a narrow 
stomach tube of  38F. Single-loop gastric bypass was 
performed, which consisted of  constructing a 40-70 mL 
sleeve gastric pouch with a jejunal exclusion of  200-220 
cm. All procedures were performed using a laparoscopic 
approach[16-18].
Following surgery, clinical controls were performed 
once a month for the first 3 postoperative months and 
every 3 mo thereafter. 
At each follow-up visit, weight loss and glycemic con-
trol status [blood glucose, hemoglobin A1c (HbA1c) and 
hypoglycemic treatment] were evaluated. Diabetes remis-
sion was defined as HbA1c values less than 6.5 without 
the use of  oral hypoglycemic treatment or insulin[11,19]. 
Statistical analysis was performed using the SPSS 17 
system (SPSS Inc., Chicago, IL, United States). Continu-
ous data were expressed as the mean ± SD, and categori-
cal variables were expressed as the percent changes. To 
compare continuous variables, an independent and/or 
paired sample t test was performed, and correlation was 
assessed using the Pearson’s linear correlation coefficients 
(r). Changes in BMI, glycemia and HbA1c were expressed 
as the percent changes vs baseline values. The χ 2 test was 
used to analyze categorical data. When the minimum ex-
pected value was < 5, the Fisher’s exact test was used. To 
adjust for major covariates and to generate predictions, 
a logistic regression (stepwise) model was applied, with 
diabetes remission at 12 mo as the dependent variable 
and gender, age, hypertension, hypercholesterolemia, 
current hypoglycemia treatment, BMI baseline value, 
glycemia and HbA1c as independent variables. All of  
the results are presented as 2-tailed values with statistical 
significance defined as P values < 0.05.
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RESULTS
A total of  53 subjects who underwent sleeve gastrecto-
my or mini-gastric bypass for obesity and diabetes were 
screened for the inclusion in this study. Of  these, 4 sub-
jects were excluded because of  surgical complications, 
7 subjects were omitted because young surgeons con-
ducted the operations and 11 subjects were removed be-
cause of  the lack of  follow-up. Thus, a total of  31 obese 
patients (15 males and 16 females; mean age: 38.32 ± 3.21 
years; BMI: 44.78 ± 4.25 kg/m2) were recruited for this 
study. All patients were diagnosed with type 2 diabetes [15 
(48.4%) on metformin and 16 (51.6%) on metformin + 
insulin], 18 subjects (58.1%) reported hypertension and 
8 presented with hypercholesterolemia. The mean gly-
cemia value was 169.87 ± 35.76, and the mean HbA1c 
level was 8.5 ± 1.0. A total of  15 subjects underwent SG 
(48.4%), and 16 patients underwent MGB (51.6%). Ma-
jor clinical and demographic characteristics of  the study 
population stratified according to type of  surgery are 
reported in Table 1.
After surgical intervention, a significant and consis-
tent reduction in BMI, glycemia and HbA1c values were 
observed relative to the baseline values (Figure 1). Strati-
fying for type of  surgery, SG and MGB were associated 
with similar percent changes in BMI (-24.33 ± 4.48 vs 
-24.19 ± 4.42, P = 0.931), glycemia (-24.30 ± 11.40 vs 
-28.42 ± 14.03, P = 0.379) and HbA1c (-22.57 ± 8.70 vs 
-22.67 ± 8.46, P = 0.975). 
Overall, significant correlations were not detected in 
the percent change from baseline to 12-mo follow-up 
between BMI and glycemia, as well as between BMI and 
HbA1c (Figure 2). Additionally, the same results were 
confirmed after stratifying based on the type of  surgery. 
Indeed, the percent change in BMI did not correlate with 
changes in glycemia (r = -0.119, P = 0.673 for SG and r = 
0.462, P = 0.071 for MGB) or with changes in HbA1c (r 
= -0.349, P = 0.202 for SG and r = -0.018, P = 0.946 for 
MGB).
As shown in Figure 3, the prevalence of  diabetes 
remission was gradually increased following surgery, re-
gardless of  the type. 
Specifically, at 3 mo post-surgical intervention, diabe-
tes remission was reported by 18 subjects (53.3% in SG 
vs 62.5% in MGB, P = 0.722). Similar results were con-
firmed at the 6-mo follow-up (53.3% for SG vs 68.8% 
for MGB, P = 0.473)
At the 12-mo follow-up, 66.7% of  subjects who 
underwent SG achieved diabetes remission vs 87.5% of  
those who underwent MGB (P = 0.220).
Interestingly, the percent change in BMI was simi-
lar between patients achieving diabetes remission and 
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Table 1  Baseline clinical and demographic characteristics of 
the study population  n  (%)
Sleeve (n  = 15) Mini-bypass (n  = 16) P  value
Age 37.26 ± 3.7 39.3 ± 2.3 0.076
Male gender 7 (46.7)   8 (50.0) 1.000
BMI 43.6 ± 2.99 45.8 ± 5.0 0.140
Diabetes treatment
Metformin ± insulin 7 (46.7)   9 (56.3) 0.724
Metformin 8 (53.3)   7 (43.7)
Glycemia 161.4 ± 31.4 177.8 ± 38.6 0.207
HbA1c   8.6 ± 1.0 8.47 ± 1.1 0.782
Hypertension 8 (53.3) 10 (62.5) 0.722
Diabetes 15 (100.0)   16 (100.0) 1.000
Hypercholesterolemia 4 (26.6)   4 (25.0) 1.000
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Figure 1  Changes in body mass index (A), glycemia (B) and hemoglobin 
A1c (C) values following surgery. HbA1c: Hemoglobin A1c; SG: Sleeve gas-
trectomy; MGB: Mini-gastric bypass; BMI: Body mass index.
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BMI: Body mass index; HbA1c: Hemoglobin A1c.
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showed that the relative risk of  diabetes increased ap-
proximately 40-fold as the BMI increased from less than 
23 kg/m2 to more than 35 kg/m2[33].
Morbid obesity has been defined by the National 
Institutes of  Health as a BMI of  greater than or equal 
to 40 kg/m2 or greater than or equal to 35 kg/m2 in the 
presence of  obesity comorbidities[13,19,20].
The prevalence of  people who are overweight or 
obese has increased dramatically in high-income coun-
tries during the past 20 years. The World Health Orga-
nization estimates that 54.3% of  women and 51.7% of  
men in the United States will be obese (BMI 30 kg/m2) 
in 2015.
Obesity is notoriously difficult to manage. Diet, 
behavioral therapy, exercise, and pharmacologic inter-
vention have traditionally been used but generally yield 
modest results. Additionally, weight regain is a common 
problem. In cases of  failed medical therapy, bariatric sur-
gery should be considered the treatment of  choice for 
severe obesity[34].
Surgical treatment of  obesity is a rapidly growing area 
of  surgical practice, reflecting the ability of  bariatric sur-
gery to achieve significant and durable weight loss, as well 
as the evolution of  safer, less-invasive procedures[35-37].
A remarkable effect of  bariatric surgery is the pro-
found and durable resolution of  type 2 diabetes clinical 
manifestations. In a meta-analysis of  134 studies that 
reported comorbidity resolution (2738 citations), bar-
iatric surgery followed by resolution of  type 2 diabetes 
was observed in 48% of  patients who underwent lapa-
roscopic adjustable gastric banding, 84% of  patients 
who underwent gastric bypass, and 98% of  patients who 
underwent biliopancreatic diversion/duodenal switch[38]. 
These data were based on reports from 22094 patients 
from January 1, 1990 to June 5, 2003.
Roux-en-Y gastric bypass (RYGB) is considered the 
gold standard bariatric procedure for achieving diabetes 
remission.
To explain the mechanisms underlying the effective-
patients who did not (-24.28 ± 4.33 vs -24.15 ± 4.53, re-
spectively, P = 0.97).
After adjusting for various clinical and demographic 
characteristics in a multivariate logistic regression analy-
sis, a high HbA1c was considered a negative predictor 
of  diabetes remission at 12 mo (OR = 0.366, 95%CI: 
0.152-0.884). Using the same regression model, MGB 
showed a clear trend towards a higher diabetes remission 
rate relative to SG (OR = 3.780, 95%CI: 0.961-14.872).
DISCUSSION
The prevalence of  type 2 diabetes has markedly increased 
in the last decade, both in the United States[20-23] and glob-
ally[24-26]. These data are correlated with a comparably 
steep increase in the prevalence of  obesity[27-29]. The pri-
mary risk factor for type 2 diabetes is obesity, and 90% of  
all patients with type 2 diabetes are either overweight or 
obese[30,31]. The National Health and Nutrition Examina-
tion Survey Ⅲ (1988-1994) data demonstrated that the 
risk for chemical diabetes is approximately 50% with a 
BMI of  greater than or equal to 30 kg/m2 and over 90% 
with a BMI of  40 kg/m2 or more[32]. The Nurses’ Health 
Study that was conducted on 84941 women (1980-1996) 
0
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Figure 2  Scatter plot of Pearson’s correlations between the percent 
change in glycemia and body mass index (A) and in hemoglobin A1c and 
body mass index (B) following surgical intervention. HbA1c: Hemoglobin 
A1c; BMI: Body mass index. 
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ness of  gastric bypass procedures in normalizing glyce-
mia, it has been suggested that removal of  the gut may 
play a major role in diabetes remission, especially be-
cause important hormones are secreted from this region. 
In 2009, Cummings reviewed the existing hypotheses 
regarding the mechanisms underlying diabetes remission. 
Based on this review, the main hypotheses include the 
ghrelin hypothesis, the upper intestinal hypothesis and 
the lower intestinal hypothesis. The ghrelin hypothesis[39] 
maintains that gherlin regulation may be disturbed fol-
lowing RYGB. Ghrelin is a hormone secreted by the 
stomach and proximal small bowel, particularly before 
meals. Its main physiological effects include increased 
appetite and fat mass increase[40]. In support of  the ghre-
lin hypothesis, several studies have shown that ghrelin 
levels are very low following RYGB. Diminished ghrelin 
secretion can decrease appetite and food intake, and re-
duced secretion might also have a role in increasing glu-
cose tolerance, as ghrelin can stimulate counter-regula-
tory hormones[41]. The lower intestinal hypothesis claims 
that intestinal shortcuts, created by bariatric surgery, 
expedite delivery of  ingested nutrients and increase glu-
cagon-like peptide-1 (GLP-1) release. GLP-1 is an incre-
tin, defined as a peptide secreted from enteroendocrine 
L-cells. These cells are found throughout the small intes-
tine and at a high density in the ileum. GLP-1 increases 
insulin secretion and has also been shown to increase 
proliferation and decrease apoptosis of  beta-cells[42]. 
Both RYGB and BPD create gastrointestinal shortcuts, 
and studies have shown that postprandial GLP-1 secre-
tion is increased post-surgery[43,44]. Therefore, it seems 
reasonable that, following surgery, GLP-1 secretion may 
be enhanced, leading to enhanced insulin secretion. This 
mechanism could also explain the increase in β-cell mass 
that is thought to accompany post-RYGB hyperinsulin-
emic hypoglycemia[45]. The upper intestinal hypothesis 
maintains that avoiding nutrient contacts with the duo-
denum is somehow key in the process through which 
diabetes is improved. The basis of  this hypothesis is that 
unknown factors or processes from the duodenum influ-
ence glucose homeostasis[39]. Rubino and Marescaux[46] 
were the first to provide support for this hypothesis. 
They experimented on a variant of  RYGB creating the 
intestinal bypass but leaving the stomach intact, which 
induced the same digestive discontinuation without re-
anastomosis. This surgery, termed duodenal-jejunal by-
pass, was tested in several studies showing an improve-
ment in T2DM without reduction in body weight[41]. 
These studies suggest that the exclusion of  the proximal 
intestine may play a role in diabetes remission.
Interestingly, sleeve gastrectomy and mini-gastric 
bypass have emerged as new and effective weight loss 
procedures[8-11,16-18,47,48].
There is increasing evidence indicating that SG 
causes early and significant improvements in glucose 
homeostasis in most morbidly obese subjects with 
T2DM[49-52].
A systematic review of  the existing literature showed 
that SG results in T2DM resolution ranging from 80% 
to 96% in morbidly obese subjects[50], a range similar to 
that in patients following RYGBP[38].
Similarly, laparoscopic mini-gastric bypass is reported 
to be a safe alternative to LRYGB, showing comparable 
efficacy in weight reduction and resolution of  metabolic 
complications, including diabetes[52-54].
Both short-term[55-57] and long-term[58,59] follow-up 
confirmed the durable effect of  this simplified proce-
dure for obese or morbidly obese patients with T2DM.
Laparoscopic mini-gastric bypass in morbidly obese 
patients with T2DM has been shown to be effective in 
prospective randomized controlled trials[55], as well as in 
extensive reports in the literature[54-59].
Gherlin regulation is disturbed following the sleeve 
gastrectomy procedure. SG was also reported to have 
a hindgut effect with increasing levels of  glucagon-like 
peptide 1 and peptide YY due to the increased transit 
time after SG[60].
Because construction of  the sleeve gastric pouch is 
the first step of  this technique, similar mechanisms are 
involved in mini-gastric bypass procedure.
The only region unaffected by SG was on the fore-
gut. Specifically, the upper intestine was not in contact 
with ingested nutrients in the GB-treated group, while 
contact was made in the SG-treated group.
Recently, Lee et al[9] published the first compara-
tive study between sleeve gastrectomy and mini-gastric 
bypass to determine the efficacy of  these treatments 
on diabetic control. Their results strongly support the 
hypothesis that duodenal exclusion may play a role in 
diabetes mellitus resolution following bariatric surgery in 
overweight patients. 
Our findings extend the observations of  Lee to se-
verely obese patients. Unlike the study conducted by Lee 
et al[9], we only enrolled patients diagnosed with severe 
obesity and a clear indication to bariatric surgery. Despite 
this difference in the recruited patient population, our 
results also confirm that MGB is associated with better 
glycemic control and a higher rate of  diabetes remission.
Although we observed a clear trend in our study, 
this did not achieve statistical significance. A multivari-
ate analysis was performed to adjust for major clinical 
and demographic variables, but because of  the relatively 
small sample size, our results need to be validated in 
larger studies. Thus, the present work could be consid-
ered a preliminary study, providing the rationale for a 
randomized prospective trial.
Further supporting this hypothesis, we reported that 
BMI changes were similar between patients achieving 
diabetes remission and patients not attaining remission. 
This finding suggests that diabetes remission may be in-
dependent from weight loss and that the type of  surgery 
may play a more relevant role. These results combined 
with the evidence that weight loss is similar following the 
sleeve gastrectomy and mini-gastric bypass procedures 
may still support the theory suggested by Lee et al[9]. 
Consequently, if  we exclude the role of  weight loss and 
Milone M et al . Bariatric surgery and diabetes remission
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both the ghrelin and hindgut theories, the only remain-
ing theory to explain the different results is the foregut 
(duodenal exclusion). 
Overall, this mechanism suggests a potential superi-
ority of  the mini-gastric bypass over the sleeve gastrec-
tomy in obtaining diabetes remission, but further data 
are needed to make this conclusion. 
While the gold standard for diabetes remission re-
mains the Roux-en-y gastric bypass because similar 
mechanisms of  diabetes remission may be involved and 
the procedure is easier to perform, the mini-gastric by-
pass could become a valuable alternative. 
Although our results appear to be encouraging and 
support mini-gastric bypass as an effective treatment 
strategy for diabetes remission, further studies are need-
ed to allow for definitive conclusions regarding the ideal 
procedure for obtaining diabetes remission.
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